ITRM Iterum Therapeutics Plc
26,046
$1.39
$0.03
(2.11%)
| Watchers | 26,046 |
| 52-Wk Low | $0.622 |
| 52-Wk High | $2.50 |
| Market Cap | $23.01M |
| Volume | 101,555.00 |
| 52-Wk High | $2.50 |
| 52-Wk Low | $0.622 |
Analysts Offer Insights on Healthcare Companies: CalciMedica (CALC), Apollomics (APLM) and Iterum Therapeutics (ITRM)TipRanks Financial Blog • about 2 months ago
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CalciMedica (CALC Research Report), Apollomics (AP...
Share to Feed
Related Stocks: NAS:ITRM...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
--Resubmission of NDA On Track for Early Q2 24 --Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24-- --Company to host conference call today at 8:30amET-- DUBLIN...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
ITRM stock results show that Iterum Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
The post ITRM...
Iterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcript...
Iterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcript...
DUBLIN, Ireland and CHICAGO, March 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
DUBLIN, Ireland and CHICAGO, March 15, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral...